Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07534592 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

A Phase 1 study, sponsored by AstraZeneca.

Active
Registry status
Phase 1
Development phase
48
Enrollment target

NCT07534592: Active Phase 1 study, sponsored by AstraZeneca.

NCT07534592 is a Phase 1 study that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07534592, a Phase 1 study, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
48 participants
Enrollment target

Study Summary

The study has 2 groups, one each focusing on co-administration of elecoglipron and atorvastatin or rosuvastatin to assess the pharmacokinetics (PK) of atorvastatin in healthy participants.

Primary Outcome

To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.

Interventions

  • DRUG Rosuvastatin
  • DRUG Atorvastatin
  • DRUG Elecoglipron

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2026-04-16
Est. Completion 2026-08-28
Phase Phase 1
AstraZeneca

1,285 total trials

What the registry record for NCT07534592 still lists

NCT07534592 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).

The record links to 0 conditions, and to 3 interventions - of which Rosuvastatin is the first listed.

NCT07534592 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07534592 about?

NCT07534592 is a clinical study titled "A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants". The study has 2 groups, one each focusing on co-administration of elecoglipron and atorvastatin or rosuvastatin to assess the pharmacokinetics (PK) of atorvastatin in healthy participants.

What is the current status of trial NCT07534592?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2026-04-16. Estimated completion is 2026-08-28.

What interventions are being tested in trial NCT07534592?

The interventions under investigation include: Rosuvastatin (DRUG), Atorvastatin (DRUG), Elecoglipron (DRUG).

Who is sponsoring clinical trial NCT07534592?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07534592's enrollment target sits among peer trials

48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07534592, the US trial registry maintained by the National Library of Medicine. NCT07534592 (small enrollment · none site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.